Letters to the Editor
Serum soluble Fas and Fas ligand (FasL) in primary Sjögren’s syndrome
F.B. Vincent1, M. Bubicich2, S. Downie-Doyle3, F. Mackay4, E.F. Morand5, M. Rischmueller6
- Centre for Inflammatory Diseases, Monash University School of Clinical Sciences at Monash Health, Melbourne, Australia. fabien.vincent@monash.edu
- Rheumatology Department, The Queen Elizabeth Hospital, Woodville, Australia.
- Rheumatology Department, The Queen Elizabeth Hospital, Woodville, Australia.
- Dept. of Immunology and Pathology, Monash Univ., Alfred Medical Research and Education Precinct (AMREP); and Dept. of Microbiology and Immunology, School of Biomedical Sciences, Dentistry & Health Sciences, Univ. of Melbourne, Australia.
- Centre for Inflammatory Diseases, Monash University School of Clinical Sciences at Monash Health, Melbourne, Australia.
- Rheumatology Department, The Queen Elizabeth Hospital, Woodville, and Discipline of Medicine, University of Adelaide, Australia.
CER11741
2019 Vol.37, N°3 ,Suppl.118
PI 0254, PF 0256
Letters to the Editor
Free to view
(click on article PDF icon to read the article)
PMID: 30789150 [PubMed]
Received: 14/09/2018
Accepted : 03/12/2018
In Press: 15/02/2019
Published: 28/08/2019
